

**Trellus Health plc**  
("Trellus Health", the "Company" or the "Group")

**Contract Signed with Leading Global CRO**

**LONDON, U.K. AND NEW YORK, U.S. (22 October 2025)** Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that, further to yesterday's announcement that it is in late stage contracting discussions, it has signed a 12 month contract (the "Contract") with one of the largest global Clinical Research Organisations (CROs), to support recruitment and enrolment optimisation for an ongoing mid-stage clinical trial in the field of immunology and inflammation. The Contract is due to commence later this year.

The clinical trials sector remains a strategic growth area for the Group and, accordingly, the Company has launched Trellus TrialSet™. This program is designed to support potential clinical trial participants by identifying individuals with low resilience, who may be hesitant to enrol in the trial, and provide structured services to strengthen their readiness.

By leveraging the Company's proprietary resilience methodology alongside behavioural science, tailored education, and personalised engagement, Trellus TrialSet™ enables participants to move from uncertainty to confidence, ensuring they are prepared to successfully enter and remain in the trial. This is expected to enhance recruitment efficiency, improve retention, and deliver cost savings for partners. The Contract, which includes an upfront fee, a monthly management fee, and milestone payments, is structured around three key performance indicators: (i) the number of potential eligible participants opting into the Trellus TrialSet™ programme, (ii) the increase in qualified participants referred for screening, and (iii) the reduction in the screen failure rate.

As further announced yesterday, Trellus Health® has also now been granted preferred vendor status ("Preferred Vendor Status") by a second leading global contract research organisation (CRO) and negotiations continue to support recruitment for an additional clinical program. Whilst the granting of Preferred Vendor Status is not revenue generating in itself, it reinforces the strength and differentiation of Trellus Health's offering in the clinical trials vertical and provides direct access to the CRO's client base as well as accelerating procurement and contracting timelines.

**Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:** *"Clinical trials continue to face challenges in recruitment, retention and study completion. We are proud to launch Trellus TrialSet™ to directly address these issues by proactively assessing and preparing participants, ensuring only those who are ready will enter the trial. This resilience-based approach is designed to significantly reduce screen failures and dropouts while delivering meaningful cost savings for our partners."*

*We are pleased to announce this partnership with a leading global CRO. While it does not immediately extend the Company's current cash runway beyond early December, it reflects our ability to secure contracts with leading CROs and represents an important step in building commercial traction. In addition, our designation as a preferred vendor by a second leading CRO for supporting recruitment for an additional clinical trial program further strengthens our position in the clinical trial vertical.*

*We will provide further updates in due course, as appropriate."*

**Regulatory Information**

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement, this inside information is now

considered to be in the public domain.

**Enquiries:**

**Trellus Health plc**

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder  
Joy Bessenger, Chief Financial Officer

<https://trellushealth.com/>

**Via Walbrook PR**

**Singer Capital Markets**

Jen Boorer / James Todd / Patrick Weaver

Tel: +44 (0)20 7496 3000

**Walbrook PR**

Paul McManus / Lianne Applegarth /  
Alice Woodings

Tel: +44 (0)20 7933 8780 or [trellus@walbrookpr.com](mailto:trellus@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/  
+44 (0)7407 804 654

**About Trellus Health plc ([www.trellushealth.com](http://www.trellushealth.com))**

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement.

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: [www.trellushealth.com](http://www.trellushealth.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTPPGQGUUPAPUG